title: [Effect of original and generic clopidogrel on prognosis in relation to different gene polymorphisms].
abstract: OBJECTIVE
  To analyze the influence of clinical and pharmacogenetic factors on the risk of resistance to original or generic clopidogrel and that of cardiovascular events (CVE) during 12 months of follow-up.
  
  
  METHODS
  Two hundred and fifty patients admitted to Moscow hospitals in October 2011 to September 2012 were examined. All the patients received clopidogrel. During their stay at hospital, venous blood samples were collected twice (before and 7-10 days after continuous clopidogrel intake). Platelet function was determined by optical aggregometry. A less than 10% reduction in platelet aggregation was taken as a resistance criterion. In addition, CYP2C9 and CYP2C19 gene polymorphisms were investigated.
  
  
  RESULTS
  Whether original or generic clopidogrel is used, the level of baseline or post-7-day ADP-induced platelet aggregation (ADP aggregation) fails to affect the risk of its resistance. Evaluation of ADP-induced platelet aggregation in patients with different CYP2C9 and CYP2C19 gene polymorphisms during the administration of original or generic clopidogrel also showed no significant differences in its resistance. During the 12-month follow-up, CVE significantly less frequently occurred as a result of the intake of original versus generic clopidogrel.
  
  
  CONCLUSIONS
  The use of original clopidogrel does not affect the risk of resistance to antiplatelet drugs, but it is associated with the lower incidence of CVE during a year.
authors.forename: D F
authors.initials: DF
authors.lastname: Mesitskaia
authors.forename: Iu M
authors.initials: IuM
authors.lastname: Nikitina
authors.forename: O V
authors.initials: OV
authors.lastname: Lomakin
authors.forename: D Iu
authors.initials: DIu
authors.lastname: Shchekochikhin
authors.forename: F Iu
authors.initials: FIu
authors.lastname: Kopylov
mesh_terms: D000368:Aged; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9 / Q000235:genetics*; D016903:Drug Monitoring; D004351:Drug Resistance / Q000235:genetics*; D057915:Drug Substitution; D016568:Drugs, Generic / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics; D010979:Platelet Function Tests / Q000379:methods; D011110:Polymorphism, Genetic; D011379:Prognosis; D013810:Therapeutic Equivalency; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D016568:Drugs, Generic; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine